Chinese expert consensus on chrono-chemotherapy for oral squamous cell carcinoma

doi:10.19438/j.cjoms.2019.01.002

China Journal of Oral and Maxillofacial Surgery ›› 2019, Vol. 17 ›› Issue (1): 7-12.doi: 10.19438/j.cjoms.2019.01.002

• Expert Consensus • Previous Articles Next Articles

Chinese expert consensus on chrono-chemotherapy for oral squamous cell carcinoma

YANG Kai¹, GUO Wei², SUN Mo-yi³, ZHENG Jia-wei², LI Long-jiang⁴, TANG Zhan-gui⁵, REN Guo-xin², CHEN Dan¹, LV Xiao-qiang¹, ZHANG Jie⁶, HAN Zheng-xue⁷, XI Qing⁸, SUN Zhi-jun⁹, CHEN Xiao-pin¹⁰, ZHANG Tao¹⁰, CHE Zong-gang¹¹, RAN Wei¹², MENG Jian¹³, HUANG Gui-lin¹⁴, TANG Hong¹, XIAO Can¹⁵

1.Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University. Chongqing 400016;
2.Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
3. Department of Oral and Maxillofacial Surgery, The Third Affiliated Hospital, Air Force Medical University School of Stomatology, Fourth Military Medical University. Xi'an 710032, Shaanxi Province;
4.Department of Head and Neck Oncology Surgery, West China Hospital of Stomatology, Sichuan University. Chengdu 610041, Sichuan Province;
5. Department of Oral and Maxillofacial Surgery, Xiangya School of Stomatology, Central South University. Changsha 410013, Hunan Province;
6.Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Peking University. Beijing 100081;
7.Department of Oromaxillofacial Head and Neck Oncology Surgery, Beijing Stomatological Hospital, Capital Medical University. Beijing 100050;
8. Stomatological Department of 1st Medical Center, Chinese PLA General Hospital. Beijing 100853;
9.Department of Oromaxillofacial Head and Neck Oncology Surgery, School and Hospital of Stomatology, Wuhan University. Wuhan 430079, Hubei Province;
10.Department of Oncology, The First Affiliated Hospital of Chongqing Medical University. Chongqing 400016;
11.Department of Oral and Maxillofacial Surgery, Zibo Central Hospital. Zibo 255036, Shandong Province;
12. Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Sun Yat-sen University. Guangzhou 510080, Guangdong Province;
13. Department of Oral and Maxillofacial Surgery, Xuzhou Central Hospital. Xuzhou 221009, Jiangsu Province;
14.Department of Oral and Maxillofacial Surgery, Stomatological Hospital, Zunyi Medical University. Zunyi 563000, Guizhou Province;
15.Department of Stomatology, The First Affiliated Hospital of Soochow University. Suzhou 215006, Jiangsu Province, China

Received:2018-11-10 Revised:2018-12-16 Online:2019-01-20 Published:2019-02-21

Abstract

Abstract: Chemotherapy is one of the main methods for treatment of oral squamous cell carcinoma, and it is also an important part of comprehensive treatment of oral squamous cell carcinoma. However, the "double-edged sword" effect of chemotherapeutic drugs in killing both cancer cells and normal cells in vivo has restricted its clinical application to a certain extent. Chrono-chemotherapy based on human circadian rhythm is safer and more effective than traditional chemotherapy, which has been confirmed by a large number of studies. In order to promote and standardize the clinical application of this technology, we organized relevant experts to discuss and formulate the chinese expert consensus. The consensus provides standardized suggestions on the principles, drug selection, administration time and methods of chrono-chemotherapy for oral squamous cell carcinoma, which can provide reference for clinical practice.

Key words: Oral squamous cell carcinoma, Chrono-chemotherapy, Circadian rhythm, Circadian clock, Expert consensus

CLC Number:

R739.8

YANG Kai, GUO Wei, SUN Mo-yi, ZHENG Jia-wei, LI Long-jiang, TANG Zhan-gui, REN Guo-xin, CHEN Dan, LV Xiao-qiang, ZHANG Jie, HAN Zheng-xue, XI Qing, SUN Zhi-jun, CHEN Xiao-pin, ZHANG Tao, CHE Zong-gang, RAN Wei, MENG Jian, HUANG Gui-lin, TANG Hong, XIAO Can. Chinese expert consensus on chrono-chemotherapy for oral squamous cell carcinoma[J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(1): 7-12.

References

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30.
[2] Pfister D, Spencer S, Adelstein D, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines^®) for head and neck cancers. Version 2.2018. Fort Washington: National Comprehensive Cancer Network (NCCN) [DB/OL]. 2018. https://www.nccn.org/professionals/physician_gls/default.aspx.
[3] 中国临床肿瘤学会指南工作委员会.头颈部肿瘤诊疗指南2018.V1[DB/OL].中国临床肿瘤学会(CSCO).2018. http://www.csco.org.cn/.
[4] 曹雨庵, 郭伟. 我国口腔鳞癌的治疗现状[J]. 实用肿瘤杂志, 2012, 27(2): 109-112.
[5] Ballesta A, Innominato PF, Dallmann R, et al.Systems chronotherapeutics[J]. Pharmacol Rev, 2017, 69(2): 161-199.
[6] Ortiz-Tudela E, Innominato PF, Rol MA, et al.Relevance of internal time and circadian robustness for cancer patients[J]. BMC Cancer, 2016, 16: 285.
[7] Ozturk N, Ozturk D, Kavakli IH, et al.Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy[J]. Int J Mol Sci, 2017, 18(10) : E2168.
[8] FitzGerald GA. Circadian rhythms.Temporal targets of drug action[J]. Science, 2014, 346(6212): 921-922.
[9] Sehgal A.Physiology flies with time[J]. Cell, 2017, 171(6):1232-1235.
[10] Turek FW.Circadian clocks: Not your grandfather's clock[J]. Science, 2016, 354(6315): 992-993.
[11] Innominato PF, Roche VP, Palesh OG, et al.The circadian timing system in clinical oncology[J]. Ann Med, 2014, 46(4): 191-207.
[12] Innominato PF, Lévi FA, Bjarnason GA.Chronotherapy and the molecular clock: Clinical implications in oncology[J]. Adv Drug Deliv Rev, 2010, 62(9-10): 979-1001.
[13] Ortiz-Tudela E, Mteyrek A, Ballesta A, et al.Cancer chronotherapeutics: experimental, theoretical, and clinical aspects[J]. Handb Exp Pharmacol, 2013, (217): 261-288.
[14] Lévi F, Okyar A, Dulong S, at el. Circadian timing in cancer treatments[J]. Annu Rev Pharmacol Toxicol, 2010, 50: 377-421.
[15] Sancar A, Lindsey-Boltz LA, Gaddameedhi S, at el. Circadian clock, cancer, and chemotherapy[J]. Biochemistry, 2015, 54(2): 110-123.
[16] 杨凯, 陈睿, 喻秀丽. 口腔癌时辰化疗[J]. 实用口腔医学杂志, 2005, 21(3): 389-391.
[17] Chen D, Cheng J, Yang K, et al.Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Onco Targets Ther, 2013, 6: 1507-1514.
[18] Ye H, Yang K, Tan XM, et al.Daily rhythm variations of the clock gene PER1 and cancer-related genes during various stages of carcinogenesis in a golden hamster model of buccal mucosa carcinoma[J]. Onco Targets Ther, 2015, 8: 1419-1426.
[19] Callaway E, Ledford H.Medicine Nobel awarded for work on circadian clocks[J]. Nature, 2017, 550(7674): 18.
[20] Zhang R, Lahens NF, Ballance HI, et al.A circadian gene expression atlas in mammals: implications for biology and medicine[J]. Proc Natl Acad Sci USA, 2014, 111(45): 16219-16224.
[21] 赵宁波, 杨凯, 唐洪, 等. 奥沙利铂对口腔鳞状细胞癌的时辰治疗[J]. 华西口腔医学杂志, 2013, 31(2): 131-135.
[22] Zhao N, Tang H, Yang K, et al.Circadian rhythm characteristics of oral squamous cell carcinoma growth in an orthotopic xenograft model[J]. Onco Targets Ther, 2013, 6: 41-46.
[23] Hori K, Zhang QH, Li HC, et al.Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow[J]. Int J Cancer, 1996, 65(3): 360-364.
[24] Blumenthal RD, Osorio L, Ochakovskaya R, et al.Regulation of tumour drug delivery by blood flow chronobiology[J]. Eur J Cancer, 2000, 36(14):1876-1884.
[25] 杨凯, 张福军, 李雅冬, 等. 时辰新辅助化疗治疗老年人口腔鳞癌的临床研究[J]. 中华老年口腔医学杂志, 2005, 3(1): 23-25.
[26] Tsuchiya Y, Ushijima K, Noguchi T, et al.Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study[J]. Chronobiol Int, 2018, 35(2): 289-294.
[27] Therasse P, Arbuck SG, Eisenhauer EA, et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
[28] Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[29] HHS, NIH, NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [DB/OL].2009. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.

Chinese expert consensus on chrono-chemotherapy for oral squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	REZIWANGULI·Yasen, MAIREPATI·Maiming, LI Chen-xi, GONG Zhong-cheng. Research progress in the role and mechanism of Porphyromonas gingivalis in promoting oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(2): 186-190.
[2]	LAN Rong, RUAN Min, HAN Nan-nan, WANG Feng. Peri-implant squamous cell carcinoma appeared after implant-restoration in the left mandible: a case report [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(2): 203-205.
[3]	LIU Heng, DUAN Xiao-feng. Research progress of ferritinophagy and related genes FTH1 and NCOA4 in oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2023, 21(1): 87-91.
[4]	JI Ping-ping, LI Li, WU Yi-fan, HOU Li-li. Effect of transcutaneous electrical acupoint stimulation on myelosuppression in patients with oral squamous cell carcinoma after induction chemotherapy [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(5): 455-460.
[5]	XU Gang, SONG Qi-yi, JIANG Wei-dong, LIU Jing-xiu. Expression and clinical significance of aquaporin 3 in oral mucosal epithelial dysplasia and oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(5): 478-482.
[6]	YANG Song, WANG Ning, ZHAO Shu-chao, LI Heng-yong, GE Sheng-you, ZHOU Kai, SONG Kai, SHANG Wei, FENG Yuan-yong. Expression and clinical significance of chemerin in oral squamous cell carcinoma patients combined with type 2 diabetes [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 390-395.
[7]	ZHANG Yi-yi, YANG Yue-yi, JU Wu-tong, ZHONG Lai-ping. Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(4): 413-416.
[8]	LIU Bing, HE Yue, PENG Xin, SUN Chang-fu, HAN Zheng-xue, WU Yu-nong, PENG Li-wei, ZHAO Yi, TAO Qian, HAN Xin-guang, LI Jin-song, SU Tong, LI Bo, ZHANG Lei, HU Yan-ping, CHEN Chuan-jun, LI Yi, LI Tie-jun, ZHAO Yi-fang. Chinese Expert consensus on the diagnosis, treatment of odontogenic keratocyst [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 209-218.
[9]	WEI Dong-liang, LI Zhi, JU Hou-yu, WU Yun-teng, GUO Wei, REN Guo-xin. Mechanism of EGFR-targeted drugs for pain relief in oral cancer [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(3): 219-224.
[10]	SUN Da-wei, ZHANG Yun, ZHU Yong. Effect of shRNA interference Rce1gene expression on the radiosensitivity of oral squamous cell carcinoma cells [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 123-128.
[11]	NUERMANGULI·Yasen, DUOLIKUN·Wufuer, BAIERNA·Wushuoer, YAN Guang-peng. The relationship between serum IL-6, IL-17, TNF-α, IFN-γ levels, clinical characteristics of60patients with oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 141-145.
[12]	QU Chu-xiang, SUN Shu-yang, ZHANG Zhi-yuan. Understanding oral cancer invasion from the perspective of genetic heterogeneity [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 193-197.
[13]	WANG Yu-xin, WANG Zhi-yong, WANG Yong-gong, WANG Hui-ming, WANG Li-zhen, TIAN Hao, YE Jin-hai, FU Kun, RUAN Min, SUN Chang-fu, SUN Guo-wen, LIU Fa-yu, XU Bi-yun, HOU Jun, LIU Bing, LIU Liang, CHEN Yong-feng, CHEN Zhan-wei, XIAO Can, LI Si-yi, LI Zhi-yong, LI Yong, LI Nan, ZHANG Chen-ping, ZHANG Dong-sheng, ZHANG Sheng, ZHANG Kai, YANG Xi, HE Wei, SU Tong, JI Tong, LIN Li-song, LUO Rui-hua, ZHAO Zhi-li, HU Qin-gang, TANG Zhan-gui, XU Wei-jia, HUANG Zhi-quan, HUANG Xiao-feng, LIANG Yu-jie, HAN Zheng-xue, HAN Wei, JIANG Can-hua, YU Jian-jun, CAI Zhi-gang, LIAO Gui-qing, LIAO Sheng-kai, CAI Hui-ming, WEI Jian-hua. Chinese expert consensus statement on the application of of indocyanine green(ICG) fluorescence imaging in the treatment of oral squamous cell carcinoma [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(1): 1-6.
[14]	LI Xing, XU Fei-hu, YANG Yun-bo, HAN Nan-nan, RUAN Min. Clinicopathological characteristics and prognostic analysis of oral squamous cell carcinoma with parotid lymph node metastasis [J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(1): 28-31.
[15]	GUO Wei, REN Guo-xin, SUN Mo-yi, KONG Yun-yi, WANG Li-zhen, BU Rong-fa, RAN Wei, TANG Zhan-gui, LI Long-jiang, MENG Jian, SUN Zhi-jun, SHANG Wei, LV Jiong, WU He-ming, ZHANG Chen-ping, HE Yue, MA Xu-hui, SONG Hao, JU Hou-yu, ZHENG Jia-wei, GONG Zhong-cheng, YANG Kai, ZHANG Jie, WU Yun-teng. Expert consensus on clinical diagnosis and treatment for Chinese oral mucosal melanoma [J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(6): 481-488.